Showing 1 - 5 results of 5 for search 'Luis Fayad', query time: 1.92s Refine Results
  1. 1
    Retratos de Jacques Gilard

    Retratos de Jacques Gilard by Luis Fayad

    Published 2009-12-01
    Get full text
    Article
  2. 2
    Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.

    Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. by Zheng Chen, Eric F Pittman, Jorge Romaguera, Luis Fayad, Michael Wang, Sattva S Neelapu, Peter McLaughlin, Larry Kwak, Nami McCarty

    Published 2013-01-01
    Get full text
    Article
  3. 3
    P1092: A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA

    P1092: A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA by Paolo Strati, Lei Feng, Jason Westin, Ranjit Nair, Sushanth Gouni, Luis Fayad, Maria Rodriguez, Dai Chihara, Luis Malpica, Raphael Steiner, Mariana Gallardo, Loretta J. Nastoupil, Sattva Neelapu

    Published 2023-08-01
    Get full text
    Article
  4. 4
    The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 studyResearch in context

    The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 studyResearch in context by Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M. Ardeshna, Roderick Johnson, Gregor Verhoef, David Cunningham, Sven de Vos, Shireen Kassam, Luis Fayad, John Radford, Sarah Bailly, Fritz Offner, David Morgan, Javier Munoz, Jerry Ping, Edith Szafer-Glusman, Karl Eckert, Jutta K. Neuenburg, Andre Goy

    Published 2023-02-01
    Get full text
    Article
  5. 5
    STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

    STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial by Matthew J. Reilley, Patricia McCoon, Carl Cook, Paul Lyne, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, John Nemunaitis, Nathan Fowler, Michael Curran, Qinying Liu, Tianyuan Zhou, Joanna Schmidt, Minji Jo, Samantha J. Lee, Mason Yamashita, Steven G. Hughes, Luis Fayad, Sarina Piha-Paul, Murali V. P. Nadella, Xiaokun Xiao, Jeff Hsu, Alexey Revenko, Brett P. Monia, A. Robert MacLeod, David S. Hong

    Published 2018-11-01
    Get full text
    Article

Search Tools: